CD8A and neoplasm: Immune correlative studies in the clinical setting have corroborated preclinical findings, showing that talimogene laherparepvec (HSV) and reovirus treatment promotes an increase in CD8 T cell density in post treatment biopsies [79,80], and measles treatment facilitates T cell priming against tumour antigens [81].